# Bortezomib in Treating Patients With Lymphoproliferative Disorders

> **NCT00023764** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 103 (actual)

## Conditions studied

- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00023764
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2015-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023764, "Bortezomib in Treating Patients With Lymphoproliferative Disorders". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00023764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*